Trial Profile
Phase II study of TAS-102 plus bevacizumab as maintenance therapy after induction chemotherapy with bevacizumab, oxaliplatin, and fluoropyrimidine in patients with metastatic colorectal cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms Switch Maintenance Study
- 19 Feb 2018 New trial record